Key points from article :
Alchemab Therapeutics, a biotechnology company based in Cambridge, has received a significant $595,000 grant from The Michael J. Fox Foundation (MJFF) to support its pioneering research into Parkinson’s disease (PD). The funding will enable Alchemab to investigate an innovative treatment approach focused on the prostaglandin pathway, which may play a key role in PD progression. This approach could potentially transform the way the disease is treated.
Alchemab’s research centres on antibodies derived from individuals who show natural resilience to Parkinson’s, aiming to uncover why some people resist the disease. Using advanced tools like proteomics, bioinformatics, and machine learning, Alchemab has identified a unique target within the prostaglandin pathway that may contribute to this resistance. If successful, this research could lead to therapies that prevent, slow, or alter the course of PD.
This grant is part of MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which supports promising research to address unmet needs in PD treatment. By backing Alchemab’s work, MJFF hopes to foster breakthroughs that bring hope to patients and their families. Both Alchemab’s CEO, Young Kwon, and MJFF’s chief program officer, Sohini Chowdhury, expressed optimism about this collaboration, which combines patient-focused research with advanced scientific techniques to explore new treatment pathways for Parkinson’s.
